Navigation Links
Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
Date:8/30/2012

SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the below listed investor conferences in September. The presentations will include an overview of the Company and an update on recent business activities.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

  • R.W. Baird Health Care Conference on Wednesday, September 5, 2012 at 3:05 p.m. Eastern Time at the New York Palace in New York.
  • Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 11, 2012 at 3:00 p.m. Eastern Time at the Grand Hyatt in New York.
  • G9: ThinkEquity Annual Growth Conference on September 12, 2012 at 10:15 a.m. Eastern Time at Le Parker Meridien in New York.
  • UBS Global Life Sciences Conference on September 19th, 2012 at 8:30 a.m. Eastern Time at the Grand Hyatt in New York.

Live audio webcasts of the presentation may be made accessible on the Investors page of the Company's website at www.optimerpharma.com.  Presentation replays are available at the same location for 90 days following the presentation.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
2. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
4. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
5. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
8. Global RFID in Healthcare and Pharmaceuticals Industry
9. Isis Pharmaceuticals to Present at the 2012 Stifel Nicolaus Healthcare Conference
10. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
11. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
Breaking Medicine News(10 mins):